Physician profile
Craig S Saffer
NPI 1245223726
$13,572.97
in general payments reported to CMS, 2019-2025
32 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,937 · 2020: $4,184 · 2021: $401 · 2022: $884 · 2023: $1,427 · 2024: $602 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $6,700.48 | 2019-2022 | |
| Intuitive Surgical, INC. | $4,224.77 | 2019-2024 | Da Vinci Sp, Da Vinci Surgical System |
| Abbvie INC. | $476.65 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $322.76 | 2022-2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay, Thinprep 2000 Processor |
| Biom'Up France Sas | $203.41 | 2020 | |
| Aspira Women'S Health INC | $191.80 | 2021-2024 | Ova1 |
| Mayne Pharma Commercial LLC | $187.06 | 2021-2025 | |
| Myovant Sciences INC. | $172.85 | 2021-2022 | |
| Daiichi Sankyo INC. | $170.52 | 2019-2024 | Injectafer |
| Coopersurgical, INC. | $92.56 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Astellas Pharma US INC | $77.01 | 2024 | Veozah |
| Allergan, INC. | $70.01 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.39 | 2019 | |
| Becton, Dickinson and Company | $60.22 | 2022-2023 | Bd Onclarity |
| Organon LLC | $55.35 | 2022-2023 | Nexplanon |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $55.20 | 2024-2025 | Solosec, Phexx, Phexxi |
| Therapeuticsmd, INC. | $52.80 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $49.08 | 2019-2020 | |
| Avion Pharmaceuticals | $40.14 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $34.89 | 2019-2022 | |
| Minerva Surgical, INC | $31.29 | 2019-2021 | |
| Baxter Healthcare | $30.17 | 2022 | |
| Exeltis, USA INC. | $29.99 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $29.75 | 2023 | Myfembree |
| Biogen, INC. | $27.10 | 2024 | |
| Medline Industries LP | $20.75 | 2024 | |
| Meditrina | $19.17 | 2025 | |
| Ethicon US, LLC | $17.52 | 2019 | |
| Olympus America INC. | $16.61 | 2023 | Pneumoliner |
| Lupin INC. | $15.65 | 2020 | |
| Channel Medsystems, INC. | $14.60 | 2022 | |
| Pfizer INC. | $14.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Saffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.